6 27

Cited 0 times in

Cited 0 times in

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”

DC Field Value Language
dc.contributor.author김도영-
dc.date.accessioned2025-08-18T05:19:10Z-
dc.date.available2025-08-18T05:19:10Z-
dc.date.issued2025-01-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/207031-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCorrespondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYoung Eun Chon-
dc.contributor.googleauthorDong Yun Kim-
dc.contributor.googleauthorHong Jae Chon-
dc.contributor.googleauthorDo Young Kim-
dc.identifier.doi10.3350/cmh.2024.0916-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid39428976-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordLenvatinib-
dc.subject.keywordSorafenib-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.citation.volume31-
dc.citation.number1-
dc.citation.startPagee98-
dc.citation.endPagee100-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.31(1) : e98-e100, 2025-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.